Search Results 41-50 of 2835 for Solid
... solid tumors studied in this trial have either spread to other parts of the body (metastatic) or cannot be removed completely with surgery (unresectable).
Part C will use the dose found in Parts A and B to find out how safe SGN-B7H4V is and if it works to treat solid tumor cancers. Participation eligibility.
Learn more about current residents in the PGY-2 Pharmacy Residency in Solid Organ Transplant at Mayo Clinic Hospital — Arizona.
The purpose of this study is to characterize the safety and tolerability of MRTX849 in patients having advanced solid tumor malignancies with KRAS G12C mutation ...
This is an open-label, two-part, multiple study to evaluate the safety and tolerability of DS-8201a in patients with advanced solid malignant tumors.
More than half of all patients who receive solid organ transplants will have an incidence of skin cancer at some point — most often a nonmelanoma cancer, ...
The first phase will be a dose escalation phase, enrolling patients with various types of solid tumors that express epidermal growth factor receptor (EGFR).
... solid tumors. Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns ...
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA) · More about research at Mayo ...
... solid tumors, determine the maximum tolerated dose (MTD) of RP-3500 in combination with Niraparib or Olaparib, examine pharmacokinetics (PK) and assess anti ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Thanks to generous benefactors, your gift today can have 5X the impact to advance AI innovation at Mayo Clinic.